Essential Amino Acids for Health & Longevity - Quick Reference Sheet

Essential Amino Acids for Health & Longevity

Created on 08/30/2026 – Quick Reference based on Evidence Review created using AI4L / Grok 4 Audit

Essential amino acid supplements deliver nine building blocks the body cannot make. The reliable signal is better walking, strength, or lean-mass holding in older or low-function people, during bed rest, and when calories are short—not muscle gain in well-fed adults. Extra powder is optional when protein is already enough. Inherited breakdown disorders and advanced kidney disease exclude some. (Full Review)

Protocol

Standard free-form dose
6–15 g complete mixture
Synthesis starts at 1.5–3 g and plateaus near 15–18 g
Half-life and splitting
Split if daily intake exceeds ~15 g
Plasma peaks in ~30–60 minutes and recedes over ~2–3 hours
Leucine-enriched older-adult approach
~35–41% leucine in the mix
Older adults often need the leucine-enriched profile and a full 10–15 g dose
Time to effect
Physical function
6–12 weeks
Walking and strength changes in older adults, not days
Lean mass
~12 weeks
Lean-mass changes measured at 12 weeks; lean leg mass held over 28-day bed rest
Immune competence
First hospital month
Fewer facility-acquired infections in older inpatients

Benefits

Contraindications
  • Phenylketonuria or other disorders of phenylalanine/tyrosine disposal
  • Maple syrup urine disease or other branched-chain ketoacid dehydrogenase defects
  • Advanced chronic kidney disease (typically eGFR <30 mL/min/1.73 m²) unless under renal-nutrition supervision
  • Acute decompensated liver failure with encephalopathy, unless a specialist protocol specifies a leucine-enriched mixture
  • Known allergy to formula ingredients (including dairy-derived flavors or tryptophan-containing blends)
Key Interactions
  • Levodopa (Parkinson disease); separate dosing by several hours
  • Monoamine oxidase inhibitors (phenelzine, tranylcypromine)
  • Insulin and sulfonylureas (insulin-releasing diabetes drugs such as glipizide, glyburide)
  • Other protein powders and BCAA products
  • Rapamycin and other mTOR inhibitors (drugs that block this growth-signaling pathway)
  • Creatine, HMB (β-hydroxy β-methylbutyrate, a leucine metabolite), and vitamin D

Risk & Side Effects

  • High: Metabolic decompensation in inborn amino-acid disorders
  • Medium: Insulin resistance and type 2 diabetes
  • Low: Nitrogen load in reduced kidney function; gastrointestinal intolerance; homocysteine rise from extra methionine
  • Speculative: Cancer promotion via chronic mTORC1 drive; shorter life from chronic high essential amino acid intake

Monitoring

Marker Target Why
eGFR Stable vs own baseline; often ≥90 mL/min/1.73 m² Nitrogen/urea handling
BUN ~10–20 mg/dL, interpreted with creatinine Excess amino acid oxidation
Fasting insulin Often <8 µIU/mL in functional practice Branched-chain/insulin-resistance watch
HbA1c Often <5.4% as a tight functional target Glycemic change on leucine-rich formulas
Homocysteine Often <10 µmol/L (some use <8) Methionine load
IGF-1 No established target; track direction vs own age-typical baseline Anabolic versus longevity tension
Plasma amino acids No established supplement target; track vs own baseline Excess leucine/BCAA signature
DEXA lean mass Rise or hold vs own baseline Composition outcome

Cadence: Labs and performance at 4 weeks, 12 weeks, then every 6–12 months, or sooner if gastrointestinal symptoms, edema, or unexpected fatigue appear

Qualitative Assessment

  • Walking ease, stair speed, and sit-to-stand
  • Training loads and recovery between sessions
  • Gastrointestinal comfort after each dose
  • Daytime energy without new sleep disruption
  • Appetite: whether the powder is displacing meals